Treating urinary tract infections in public sector primary healthcare facilities in Cape Town, South Africa: A pharmaceutical perspective
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i7.16258Keywords:
urinary tract infectionsAbstract
Background. Antibiotic resistance is a global healthcare burden complicating the management of infections. Urinary tract infections (UTIs) are commonly treated in primary care. Managing UTIs appropriately in primary care can combat antibiotic resistance. The treatment practices for UTIs in primary care in Western Cape Province, South Africa, are not well described.
Objectives. To describe treatment of UTIs in adults in primary care in the Cape Town metropole public sector of the Western Cape. Method. A retrospective multicentre medical records review of patients diagnosed with UTIs was conducted during 1 October 2020 - 28 February 2021. Six public sector primary healthcare facilities were included in the study through random selection from three of the four substructures in the Cape Town metropole. Medical records of adult patients diagnosed with UTIs, through clinical diagnosis or microbiological testing, were identified via a selective sampling process. Data were collected from medical records using a standardised data collection tool.
Results. A total of 401 UTI episodes occurred in 383 patients during the study period. The majority of UTI episodes (84.3%) occurred in females, complicated UTIs (74.1%) were more common than uncomplicated UTIs, and nitrofurantoin (57.1%) was frequently prescribed, followed by ciprofloxacin (39.7%). Compliance with urine microscopy recommendations was low (6.7%), and antibiotics were appropriately selected in 75.0% of uncomplicated and 70.0% of complicated UTI episodes.
Conclusion. Interventions are required to improve compliance with treatment recommendations as per the standard treatment guidelines, especially when selecting the appropriate antibiotic, duration of therapy and urine microscopy.
References
O’Neil J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. London: Review on Antimicrobial Resistance, 2014. https://wellcomecollection.org/works/rdpck35v (accessed 20 June 2021).
Chandra P, Unnikrishnan MK, Vandana KE, et al. Antimicrobial resistance and the post antibiotic era: Better late than never effort. Expert Opin Drug Saf 2021;20(11):1375-1390. https://doi.org/10.1080/1 4740338.2021.1928633
Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007 - 09. J Antimicrob Chemother 2014;69(1):234-240. https://doi.org/10.1093/jac/dkt301 4. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010 - 2011. JAMA 2016;315(17):1864-1873. https://doi.org/10.1001/jama.2016.4151
Department of Health Standing Medical Advisory Committee, UK. The path of least resistance: Report of Sub-group on Antimicrobial Resistance. London: Department of Health, 1998.
Centers for Disease Control and Prevention, USA. Measuring outpatient antibiotic prescribing. 2019. https://www.cdc.gov/antibiotic-use/community/programs-measurement/measuring-antibiotic-prescribing.html (accessed 15 July 2021).
World Health Organization. Global Action Plan on Antimicrobial Resistance. 2015. https://apps.who.int/iris/handle/10665/193736 (accessed 30 June 2021).
CoxJA,VliegheE,MendelsonM,etal.Antibioticstewardshipinlow-andmiddle-incomecountries:The same but different? Clin Microbiol Infect 2017;23(11):812-818. https://doi.org/10.1016/j.cmi.2017.07.010
Chetty S, Reddy M, Ramsamy Y, Naidoo A, Essack S. Antimicrobial stewardship in South Africa: A scoping review of the published literature. JAC Antimicrob Resist 2019;1(3):dlz060. https://academic.oup.com/jacamr/article/1/3/dlz060/5645376
Peters SM, Werner J, Willems B. Antimicrobial stewardship in the Western Cape: A situational analysis of existing facility-level initiatives. S Afr Med J 2021;111(5):421-425. https://doi.org/10.7196/ SAMJ.2021.v111i5.14645
National Department of Health, South Africa. Antimicrobial Resistance National Strategy Framework 2014 - 2024. 2014. https://health-e.org.za/wp-content/uploads/2015/09/Antimicrobial-Resistance- National-Strategy-Framework-2014-2024.pdf (accessed 14 June 2021).
National Department of Health, South Africa. Primary Healthcare Standard Treatment Guidelines and Essential Medicines List 6th edition – 2018. Pretoria: NDoH, 2018. https://www.knowledgehub.org.za/ elibrary/primary-healthcare-standard-treatment-guidelines-and-essential-medicines-list-6th-edition (accessed 20 January 2021).
Gasson J, Blockman M, Willems B. Antibiotic prescribing practice and adherence to guidelines in primary care in the Cape Town metro district, South Africa. S Afr Med J 2018;108(4):304-310. https:// doi.org/10.7196/SAMJ.2017.v108i4.12564
Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol 2019:11:1756287219832172. https://doi.org/10.1177/1756287219832172 15. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):103-120. https://doi.org/10.1093/cid/ciq257
World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early implementation 2016 - 2017. Geneva: WHO, 2017. https://www.who.int/docs/ default-source/searo/amr/global-antimicrobial-resistance-surveillance-system-(glass)-report-early- implementation-2016-2017.pdfsfvrsn=ea19cc4a_2 (accessed 10 July 2021).
Öztürk R, Murt A. Epidemiology of urological infections: A global burden. World J Urol 2020;38(11):2669-2679. https://doi.org/10.1007/s00345-019-03071-4
Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol 2018;219(1):40-51. https://doi.org/10.1016/j.ajog.2017.12.231
Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2019, Issue 11. Art. No.: CD000490. https://doi.org/10.1002/14651858.CD000490.pub4
Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019;68(10):e83-e110. https://doi.org/10.1093/cid/ciy1121
Fernandez J, Coyle E. Urinary tract infections and prostatitis. In: DiPiro J, Yee GC, Posey LM, Haines ST, Nolin TD, Ellingrod V, eds. Pharmacotherapy: A Pathophysiological Approach. 11th ed. New York: McGraw-Hill Education, 2019.
Bosch FJ, van Vuuren C, Joubert G. Antimicrobial resistance patterns in outpatient urinary tract infections – the constant need to revise prescribing habits. S Afr Med J 2011;101(10):328-331.
Nzalie RN-T, Gonsu HK, Koulla-Shiro S. Bacterial etiology and antibiotic resistance profile of community-acquired urinary tract infections in a Cameroonian city. Int J Microbiol 2016;2016:3240268. https://doi.org/10.1155/2016/3240268
Bhola P, Mvelase NR, Balakrishna Y, Mlisana KP, Swe-Han KS. Antimicrobial susceptibility patterns of uropathogens isolated from pregnant women in KwaZulu-Natal Province: 2011 - 2016. S Afr Med J 2020;110(9):872-876. https://doi.org/10.7196/SAMJ.2020.v110i9.14468
Fourie JL, Claassen FM, Myburgh JJ. Causative pathogens and antibiotic resistance in community- acquired urinary tract infections in central South Africa. S Afr Med J 2021;111(2):124-128. https://doi.org/10.7196/SAMJ.2021.v111i2.14905
Lewis DA, Gumede LY, van der Hoven LA, et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013;103(6):377-381. https://doi.org/10.7196/SAMJ.6722
Wagenlehner FME, Johansen TEB, Cai T, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol 2020;17(10):586-600. https://doi.org/10.1038/ s41585-020-0362-4
European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. 2018. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products (accessed 12 June 2021).
US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics (accessed 28 July 2021).
National Department of Health, South Africa. Circular H53/2019 Notice: Risk of serious adverse effects associated with fluoroquinolones. 2019.
Naing L, Winn T, Rusli B. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 2006;1:9-14.
Bonkat G, Pickard R, Bartoletti R, et al. EAU Guidelines on Urological Infections. 2018. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-Infections-2018-large-text.pdf (accessed 10 June 2021).
Sabih A, Leslie S. Complicated urinary tract infections. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing, 2022. https://pubmed.ncbi.nlm.nih.gov/28613784/ (accessed 10 June 2021).
National Department of Health, South Africa. Circular H74/2020: Antibiotic selection and dosing for empiric treatment of urinary tract infections. 2020.
Wattengel B, DiTursi S, Schroeck J, Sellick J, Mergenhagen K. Outpatient antimicrobial stewardship: Targets for urinary tract infections. Am J Infect Control 2020;48(9):1009-1012. https://doi.org/10.1016/j.ajic.2019.12.018
Cai T, Palagin I, Brunelli R, et al. Office-based approach to urinary tract infections in 50 000 patients: Results from the REWIND study. Int J Antimicrob Agents 2020;56(1):105966. https://doi. org/10.1016/j.ijantimicag.2020.105966
Ingalsbe M, Wojciechowski A, Smith K, Mergenhagen K. Effectiveness and safety of nitrofurantoin in outpatient male veterans. Ther Adv Urol 2015;7(4):186-193. https://doi.org/10.1177/1756287215581556
Wolterink I, Verheij T, Platteel T, et al. Nitrofurantoin failure in elderly men: A retrospective observational study. Antibiotics 2020;9(5):3-7. https://doi.org/10.3390/antibiotics9050211
O’Kane DB, Dave SK, Gore N, et al. Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2016, Issue 4. Art. No.: CD010745. https://doi.org/10.1002/14651858.CD010745.pub2
Bayer HealthCare Pharmaceuticals Inc. CIPRO (ciprofloxacin hydrochloride). 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf (accessed 1 July 2021).
National Department of Health, South Africa. Primary Healthcare Standard Treatment Guidelines and Essential Medicines List for South Africa – 2020. 7th ed. Pretoria: NDoH, 2020. https://www. knowledgehub.org.za/elibrary/primary-healthcare-phc-standard-treatment-guidelines-and-essential- medicines-list-south (accessed 20 January 2021).
Garau J, Bassetti M. Role of pharmacists in antimicrobial stewardship programmes. Int J Clin Pharm 2018;40(5):948-952. https://doi.org/10.1007/s11096-018-0675-z
Downloads
Published
Issue
Section
License
Copyright (c) 2022 N Keuler, Y Johnson, R Coetzee
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
